Cambridge University Hospital is the first secondary care site to go live in the DELTA trial, introducing CytospongeTM - TFF3 as a triage test for endoscopy to identify Barrett’s oesophagus, early cancer and other oesophageal conditions. From the beginning of September the Fitzgerald team began recruiting patients from GP referrals with heartburn and those requiring Barrett's Oesophagus surveillance. This effort is helping contribute to decrease the current COVID back-log. We look forward to other Eastern region hospitals coming on board in the near future followed by hospitals across the UK in the new year.
